🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

EMCURE PHARMACEUTICALS L EMCURE NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.emcure.com
Company Profile ↓
₹1,813.10
+41.61% 1Y
Mkt Cap₹34,374.48 Cr
P/E37.18
P/B6.87
Div. Yield0.17%
52W High₹1,880.20
52W Low₹1,271.80
Book Value₹261.09
EPS (TTM)₹48.77

Company Overview

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 18.7%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 25.1%.

Consistent Profit Growth

Net profit has compounded at 20.2% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 15.8% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 37.2, below the sector median of 40.0.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.31.

Recent Developments

  • Mar 2026 Revenue of ₹9,203.54 Cr (+16.6% YoY); net profit ₹924.36 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +16.6%, earnings +35.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 15.8%, profit CAGR 20.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:15.77%
1 Year:16.56%

Compounded Profit Growth

5 Years:20.22%
1 Year:35.67%

Stock Price Performance

1 Year:+41.61%
6 Months:+17.69%
3 Months:+10.62%
1 Month:+6.30%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 89% of range
₹1,271.80 ₹1,880.20
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)53.49 · Neutral
Price Performance
1M+6.30%
3M+10.62%
6M+17.69%
1Y+41.61%
Valuation vs Sector

P/E of 37.18 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 25.1%.
  • Compounding revenue at 15.8% over 5 years.
  • Profit CAGR of 20.2% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
37.18
Industry PE
39.97
Forward P/E
24.27
PEG Ratio
-
Book Value
₹261.09
Price to Book
6.87
P/S
3.70
EV/EBITDA
19.79
Dividend Yield
0.17%

Growth (CAGR)

Revenue 5Y
15.77%
Profit 5Y
20.22%
Revenue (YoY)
16.56%
Earnings (YoY)
35.67%

Profitability & Returns

ROCE
25.10%
ROE
18.67%
ROA
9.62%
Profit Margin
10.04%
Op Margin
14.92%
Gross Margin
60.26%
EPS (Latest Qtr)
₹12.84
EPS (TTM)
₹48.77

Balance Sheet & Liquidity

Debt/Equity
0.31
Quick Ratio
0.82
Current Ratio
1.43
Debt
₹1,521.24 Cr
Total Assets
₹9,612.48 Cr
Current Assets
₹5,612.10 Cr
Working Capital
₹1,699.86 Cr

Ownership

Promoter Holding
81.70%
Chg in Prom Hold
-0.01%
FII / Inst Holding
5.45%
Chg in FII Hold
0.04%

Financial Snapshot

Enterprise Value
₹34,374.48 Cr
Total Revenue (TTM)
₹9,203.54 Cr
EBITDA
₹1,845.86 Cr
Free Cash Flow
₹395.86 Cr
Operating Cash Flow
₹943.54 Cr
Shares Outstanding
₹18.96 Cr
Gross Margin
60.26%
Payout Ratio
6.15%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 EMCURE EMCURE PHARMACEUTICALS L NIFTY_SMALLNSEPHARMA 1,813.10 37.18 ₹34,374.48 Cr 0.17% 25.10% 18.67% 15.77% 20.22%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 1,556.00 Cr1,663.00 Cr1,668.00 Cr1,771.00 Cr1,815.00 Cr2,002.00 Cr-2,116.24 Cr2,100.54 Cr2,269.82 Cr2,363.48 Cr2,469.70 Cr
Cost of Revenue -------892.11 Cr802.01 Cr889.53 Cr962.43 Cr1,003.09 Cr
Gross Profit -------1,224.13 Cr1,298.52 Cr1,380.29 Cr1,401.05 Cr1,466.61 Cr
Operating Expenses 1,261.00 Cr1,334.00 Cr1,374.00 Cr1,460.00 Cr1,479.00 Cr1,621.00 Cr-931.05 Cr994.09 Cr1,045.81 Cr1,045.61 Cr1,087.41 Cr
Operating Income 229.00 Cr259.00 Cr210.00 Cr220.00 Cr242.00 Cr284.00 Cr-293.09 Cr304.43 Cr334.48 Cr355.44 Cr379.21 Cr
EBITDA 296.00 Cr329.00 Cr294.00 Cr311.00 Cr336.00 Cr381.00 Cr-396.48 Cr416.97 Cr478.60 Cr456.45 Cr493.84 Cr
Interest Expense 52.00 Cr59.00 Cr61.00 Cr65.00 Cr59.00 Cr46.00 Cr-39.02 Cr26.75 Cr32.54 Cr37.98 Cr46.40 Cr
Pretax Income 191.00 Cr198.00 Cr171.00 Cr167.00 Cr207.00 Cr273.00 Cr-260.61 Cr290.76 Cr341.42 Cr313.79 Cr341.18 Cr
Tax Provision 49.66 Cr51.48 Cr51.30 Cr45.09 Cr53.82 Cr70.98 Cr-63.38 Cr75.97 Cr90.05 Cr82.42 Cr97.44 Cr
Net Income 141.00 Cr146.00 Cr120.00 Cr121.00 Cr153.00 Cr202.00 Cr-188.96 Cr206.95 Cr243.46 Cr230.54 Cr243.40 Cr
Diluted EPS 7.217.696.276.367.9510.29-9.9710.9212.8512.1612.84

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 4,717.00 Cr5,049.00 Cr5,033.00 Cr-5,931.08 Cr6,581.99 Cr7,896.00 Cr9,203.54 Cr
Cost of Revenue ----2,408.09 Cr2,609.58 Cr3,146.60 Cr3,657.06 Cr
Gross Profit ----3,522.98 Cr3,972.41 Cr4,749.39 Cr5,546.48 Cr
Operating Expenses 3,968.00 Cr4,340.00 Cr3,817.00 Cr-2,582.36 Cr3,055.10 Cr3,664.67 Cr4,172.92 Cr
Operating Income 482.00 Cr387.00 Cr966.00 Cr-940.63 Cr917.32 Cr1,084.73 Cr1,373.56 Cr
EBITDA 749.00 Cr708.00 Cr1,216.00 Cr-1,170.25 Cr1,240.33 Cr1,531.31 Cr1,845.86 Cr
Interest Expense 223.00 Cr257.00 Cr155.00 Cr-162.91 Cr200.69 Cr175.78 Cr143.67 Cr
Pretax Income 331.00 Cr105.00 Cr652.00 Cr-747.22 Cr727.23 Cr971.35 Cr1,287.14 Cr
Tax Provision 122.47 Cr4.20 Cr234.72 Cr-185.37 Cr199.65 Cr263.88 Cr345.87 Cr
Net Income 209.00 Cr101.00 Cr419.00 Cr-532.02 Cr498.18 Cr681.33 Cr924.36 Cr
Diluted EPS 10.794.6223.15-29.4327.5736.4348.77

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 5,577.00 Cr5,960.00 Cr6,768.00 Cr-6,672.53 Cr7,806.16 Cr8,232.72 Cr9,612.48 Cr
Current Assets ----3,835.91 Cr4,259.91 Cr4,555.86 Cr5,612.10 Cr
Cash & Equivalents ----56.37 Cr108.96 Cr121.82 Cr136.66 Cr
Inventory ----1,383.03 Cr1,525.10 Cr1,931.81 Cr2,397.87 Cr
Receivables ----1,648.30 Cr1,858.81 Cr2,002.24 Cr2,562.66 Cr
Total Liabilities ----4,022.87 Cr4,684.40 Cr3,591.17 Cr4,635.81 Cr
Current Liabilities ----3,019.19 Cr3,210.47 Cr2,668.27 Cr3,912.24 Cr
Long Term Debt ----744.13 Cr766.60 Cr189.94 Cr252.21 Cr
Total Debt 2,128.00 Cr2,327.00 Cr2,310.00 Cr-2,334.30 Cr2,334.97 Cr1,022.75 Cr1,521.24 Cr
Total Equity 1,835.00 Cr1,912.00 Cr2,273.00 Cr-2,501.13 Cr2,952.28 Cr4,446.19 Cr4,950.03 Cr
Shares Outstanding ----18.91 Cr18.91 Cr18.95 Cr18.96 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 444.00 Cr500.00 Cr704.00 Cr-746.85 Cr1,097.24 Cr851.71 Cr943.54 Cr
Investing Cash Flow -409.00 Cr-168.00 Cr-256.00 Cr--467.69 Cr-712.51 Cr-94.00 Cr-1,193.06 Cr
Financing Cash Flow -735.00 Cr-301.00 Cr-189.00 Cr--145.40 Cr-164.21 Cr-813.96 Cr343.43 Cr
Capital Expenditure -405.00 Cr-138.00 Cr-133.00 Cr--403.36 Cr-307.13 Cr-406.93 Cr-547.69 Cr
Free Cash Flow 39.00 Cr362.00 Cr571.00 Cr-343.49 Cr790.11 Cr444.78 Cr395.86 Cr
Net Change in Cash -700.00 Cr32.00 Cr259.00 Cr-133.77 Cr220.52 Cr-56.25 Cr93.92 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ----59.4%60.4%60.1%60.3%
Operating Margin % 10.2%7.7%19.2%-15.9%13.9%13.7%14.9%
Net Margin % 4.4%2.0%8.3%-9.0%7.6%8.6%10.0%
ROE % 11.4%5.3%18.4%-21.3%16.9%15.3%18.7%
ROCE % ----25.7%20.0%19.5%24.1%

Shareholding Pattern

Insiders
81.70%
Institutions
5.45%
Public Float
29.80%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for EMCURE

Google News ue, 14 Jul 2026

Pharma stock in focus after agreement to acquire remaining 12% stake in its subsidiary - MSN

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOMmRPbVBaSDdWeFhkMzUzMmdzZUcxMEE2TUhheEY1dGdWcWNvRmlaSC1IalpMUHk4MFJSWTZDWFR1ZUt0WlNsd3Jib21CaG4zV3FKU3NWRVFJSnpTanc1bDNBQkwzamdFUmN2M0g3VWNJY1BrVXEwZk1udkg2Q215SHN3b3RRX19LSUc0WV…

Google News ue, 14 Jul 2026

Stocks in focus: Biocon, Route Mobile, BEL among 11 companies to watch - BusinessLine

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPVnZPNFFpbHA4M2VoRUItYnFxbUM0R01VQW9DTWJGR3kyejZBcEFRdUhyVjFZeGl3aEowdHplTTlDYnhDd3gtS2ZoTjZwdjJPNzh2WjFVQUgtRnhtR0xXbTg5V01KeUZ3Y242VFZjdnB1cVFUMERLT2xhd3ctNlQ1ZXBuQlJWeVJYVEZfSz…

Google News ue, 14 Jul 2026

Emcure Pharmaceuticals to Acquire Remaining 12.05% Stake in Gennova for ₹231.87 Crore - scanx.trade

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQUE91REJ5QWdPWnhFd1lsbXRDR2xHUjJiTDRwMmRZY2FSUVVuX2xVMmZHTktTb0lDYW9QLXN2M0h2dnVJWm03dWxNbXZITXl6ZFJMdFF3eGM1MjRVSkN6SVVMbmxnVWpMWG1rN0lJQmNzRU5pa25FMUlhc2NJUnFwLXlQWHRtMFozbmZfUU…

Google News Mon, 13 Jul 2026

Emcure to make Gennova Biopharma wholly owned subsidiary with ₹232 crore stake buyout - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxQMWdhTFh4ekZpajhyYVh3Q1dIYUEwMDdzbERsR2tsNHV5YUFYYXFCR2g4M0VsMUtCYk1iNW1JcldmQWxaTlgzWUNBRzEtT0theXVDdllIeWVrelV1aWJabGtVSzgyYlNidkFmYXFtbDk5NmVrTTM5SHQtQWZ5ZW5DdVRfSTB4RkI4cmpsNW…

Google News hu, 25 Jun 2026

Promoter sells 3% stake in stainless steel wires maker Bansal Wire - TradingView

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNUlAxRTJQSUtlMi1RX0Z2emtfc0YtN1hMSzJHRzJVZ2pZemNzOUVOUllaNmRNQkttQ3pCblNQWHlucjVVXzFmTnRHbUs5Z1FHSVJVQzVIaDJGQ3BQX2JoTDdqRlRQZDhjM3BkR1VKbUxJeHFlejU1N1loWGJRSGFiNW1ZaTB3bHVHaGxnQX…

Google News Mon, 13 Jul 2026

Emcure buys remaining 12.05% in Gennova to take full control - The Economic Times

<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxPNlo3Tnh5ODFyLTVLMkxFekRvRlBjLUd0MC1iTzVOWExtRDNxbEQ3d1JSc05JVVJRcktrb0R6WF9Nb2JiMkF4VDN0LU0tZjlUQ3Z0VkdXUTViTDYyNFVDU3NycXNRRmdzVlJaSzJIVTBqMnpibWNZTm5hQU5WZlFLZFZJc2dncWtzZG9HVX…

EMCURE — Frequently Asked Questions

What is the current share price of EMCURE PHARMACEUTICALS L (EMCURE)?

As of 2026-07-15 09:52 IST, EMCURE PHARMACEUTICALS L (EMCURE) trades at ₹1,813.10 on NSE. Its 52-week range is ₹1,271.80 to ₹1,880.20.

What is the market capitalisation of EMCURE?

EMCURE PHARMACEUTICALS L (EMCURE) has a market capitalisation of ₹34,374.48 Cr on NSE.

What is the P/E ratio of EMCURE?

EMCURE trades at a trailing price-to-earnings (P/E) ratio of 37.18. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 6.87.

Does EMCURE pay a dividend?

EMCURE PHARMACEUTICALS L (EMCURE) currently offers a dividend yield of 0.17%.

What is the return on equity (ROE) of EMCURE?

EMCURE has a return on equity (ROE) of 18.67%. Its return on capital employed (ROCE) is 25.10%.

Is EMCURE a good stock to buy?

This page provides a data-driven analysis of EMCURE PHARMACEUTICALS L (EMCURE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space